ArticleLancet regional health. Americas2022
Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey.
Article in Lancet regional health. Americas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Implementing a multi-centric cohort study during the SARS-CoV-2 pandemic in a resource-constrained setting: challenges, adaptive solutions, and lessons from Brazil.Archives of public health = Archives belges de sante publique · 2026Article
- Demand creation for testing and Covid-19 surveillance indicators in the Covid-19 Testing, Isolation, Quarantine, and Telemonitoring Study.Revista de saude publica · 2026Article
- Mental health during the Covid-19 pandemic: reports from health professionals in Rio de Janeiro.Revista de saude publica · 2026Article
- History of self-reported COVID-19 cases and hospitalizations in the Brazilian population: a countrywide survey.International journal of epidemiology · 2026Article
- Acceptability and usability of COVID-19 antigen self-test in populations under socioeconomic vulnerability in Brazil: A cross-sectional study.PLOS global public health · 2026Article
- Adoption of Covid-19 preventive behaviors in the community: Salvador and Rio de Janeiro.Revista de saude publica · 2026Article
- Prevalence of chronic non-communicable diseases and multimorbidity among adults living in slums in Rio de Janeiro, Brazil: a population-based survey.International journal for equity in health · 2025Article
- Article
- Food insecurity and associated factors during the COVID-19 pandemic in a vulnerable population in Rio de Janeiro: A primary care registry-based survey.PLOS global public health · 2025Article
- Molecular and seroepidemiology of SARS-CoV-2 among influenza-like illness and severe Acute respiratory illness cases in selected health facilities in Ethiopia.Frontiers in public health · 2025Article
- SARS-CoV-2 transmission in a highly vulnerable population of Brazil: a household cohort study.Lancet regional health. Americas · 2024Article
- Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.JAMA pediatrics · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Background: COVID-19 serosurveys allow for the monitoring of the level of SARS-CoV-2 transmission and support data-driven decisions. We estimated the seroprevalence of anti-SARS-CoV-2 antibodies in a large Methods: A population-based panel study was conducted in Complexo de Manguinhos (16 Findings: 4,033 participants were included (from Sep/2020 to Feb/2021, 22 epidemic weeks), the median age was 39·8 years (IQR:21·8-57·7), 61% were female, 41% were mixed-race ( Interpretation: We found a significantly higher prevalence of anti-S IgG antibodies than initially anticipated. Disparities in estimates obtained using different serological assays highlight the need for cautious interpretation of serosurveys estimates given the heterogeneity of exposure in communities, loss of immunological biomarkers, serological antigen target, and variant-specific test affinity. Funding: Fundação Oswaldo Cruz, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), the European Union's Horizon 2020 research and innovation programme, Royal Society, Serrapilheira Institute, and FAPESP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.